A new player has emerged in a bid to acquire the materials manufacturer.
News & Analysis: Merck KGAA
Big Pharma is out with encouraging cancer-survival data and response rates prior to the June ASCO event.
The good news keeps piling up for avelumab and its developing duo.
With a market valuation of $205 billion, this pharmaceutical giant is looking to claim its stake in the multibillion-dollar cancer immunotherapy space.